Download Files:

Abaloparatide

$170$520

Products Details

Product Description

– Abaloparatide (BA 058) is a parathyroid hormone receptor 1 (PTHR1) analog. Abaloparatide also is a selective PTHR1 activator. Abaloparatide enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide enhances bone formation and cortical structure in mice. Abaloparatide has the potential for the research of osteoporosis[1][2].

Web ID

– HY-108742

Storage Temperature

– -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)

Shipping

– Blue Ice

Applications

– Metabolism-protein/nucleotide metabolism

Molecular Formula

– C174H300N56O49

References

– [1]Sahbani K, et al. Abaloparatide exhibits greater osteoanabolic response and higher cAMP stimulation and β-arrestin recruitment than teriparatide. Physiol Rep. 2019 Oct;7(19):e14225.|[2]Varela A, et al. One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption. J Bone Miner Res. 2017 Jan;32(1):24-33.

CAS Number

– 247062-33-5

Molecular Weight

– 3960.59

Compound Purity

– 99.94

SMILES

– [AVSEHQLLHDKGKSIQDLRRRELLEKLL-{Aib}-KLHTA-NH2]

Clinical Information

– Launched

Research Area

– Metabolic Disease

Solubility

– DMSO : 25 mg/mL (ultrasonic)

Target

– Arrestin;Thyroid Hormone Receptor

Pathway

– GPCR/G Protein;Vitamin D Related/Nuclear Receptor

Product type

– Peptides

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.